What is NDC 24979-247?

24979-247 is the product NDC for Forfivo XL (bupropion hydrochloride), Bupropion hydrochloride 450 mg/1 tablet, film coated, extended release, listed with the FDA by Upsher-Smith Laboratories, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Upsher-Smith Laboratories, LLC, NDC labeler code 24979. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Forfivo XL?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Forfivo XL NDC 24979-247 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)24979-247Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24979-0247Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24979-247-06	24979024706	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24979-247-06)Marketed from Dec 15, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Forfivo XLSuffix: XL
Generic name (nonproprietary): bupropion hydrochloride
Active ingredients: Bupropion hydrochloride — 450 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Upsher-Smith Laboratories, LLCNDC labeler code 24979
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022497
Marketing start: Dec 15, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Dopamine Uptake Inhibitors (Mechanism)Increased Dopamine Activity (Physiologic effect)Increased Norepinephrine Activity (Physiologic effect)Norepinephrine Uptake Inhibitors (Mechanism)
Identifiers: Product ID 24979-247_96a5dcb3-5d09-4357-96e3-8005ef094b2cSPL ID 96a5dcb3-5d09-4357-96e3-8005ef094b2cSPL set ID 80b01182-dc94-4990-8ebb-55c306d7e536RxCUI 1232585, 1232591UNII ZG7E5POY8OUPC 0324979247069
Pharmacologic class: Aminoketone

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424979024706 followed by a unit qualifier and the quantity

Package 24979-0247-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 6, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

FORFIVO XL (bupropion hydrochloride extended-release tablets) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies ( 14 )] . The physician who elects to use FO…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 24979-247

What is NDC 24979-247?: 24979-247 is the product NDC for Forfivo XL (bupropion hydrochloride), Bupropion hydrochloride 450 mg/1 tablet, film coated, extended release, listed with the FDA by Upsher-Smith Laboratories, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Forfivo XL (Bupropion hydrochloride).
What is the active ingredient?: Bupropion hydrochloride.
Who is the labeler?: Upsher-Smith Laboratories, LLC, NDC labeler code 24979. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Forfivo XL?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under NDA 022497

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022497
Product	Strength	Form · route	Labeler	Product NDC
BUPROPION HCl ER (XL)bupropion hcl er	Bupropion hydrochloride 450 mg/1	Tablet, Extended releaseOral	Lifestar Pharma LLC	70756-830
bupropion hydrochloride	Bupropion hydrochloride 450 mg/1	Tablet, Film coated, Extended releaseOral	Upsher-Smith Laboratories, LLC	24979-248

Forfivo XL (Bupropion hydrochloride) NDC 24979-247